The diagnostic value of quantitative analysis of ASL, DSC-MRI and DKI in the Grading of Cerebral Gliomas: A Meta-Analysis&nbsp;

doi:10.21203/rs.3.rs-22117/v3

PDF

Research

The diagnostic value of quantitative analysis of ASL, DSC-MRI and DKI in the Grading of Cerebral Gliomas: A Meta-Analysis

https://doi.org/10.21203/rs.3.rs-22117/v3

This work is licensed under a CC BY 4.0 License

Journal Publication

published 24 Aug, 2020

Read the published version in Radiation Oncology →

You are reading this latest preprint version

Objective: To perform quantitative analysis on the efficacy of using relative cerebral blood flow (rCBF) in arterial spin labeling (ASL), relative cerebral blood volume (rCBV) in dynamic magnetic sensitivity contrast-enhanced magnetic resonance imaging (DSC-MRI), and mean kurtosis (MK) in diffusion kurtosis imaging (DKI) to grade cerebral gliomas.

Methods: Literature regarding ASL, DSC-MRI, or DKI in cerebral gliomas grading in both English and Chinese were searched from PubMed, Embase, Web of Science, CBM, China National Knowledge Infrastructure (CNKI), and Wanfang Database as of 2019. A meta-analysis was performed to evaluate the efficacy of ASL, DSC-MRI, and DKI in the grading of cerebral gliomas.

Result: A total of 54 articles (11 in Chinese and 43 in English) were included. Three quantitative parameters in the grading of cerebral gliomas, rCBF in ASL, rCBV in DSC-MRI, and MK in DKI had the pooled sensitivity of 0.88 [95%CI (0.83,0.92)], 0.92 [95%CI (0.83,0.96)], 0.88 [95%CI (0.82,0.92)], and the pooled specificity of 0.91 [95%CI (0.84,0.94)], 0.81 [95%CI (0.73,0.88)], 0.86 [95%CI (0.78,0.91)] respectively. The pooled area under the curve (AUC) were 0.95 [95%CI (0.93,0.97)], 0.91 [95%CI (0.89,0.94)], 0.93 [95%CI (0.91,0.95)] respectively.

Conclusion: Quantitative parameters rCBF, rCBV and MK have high diagnostic accuracy for preoperative grading of cerebral gliomas.

Oncology

gliomas

grading

MRI

Meta-analysis

Gliomas are the most common primary tumors of the central nervous system, accounting for about 45% of all intracranial tumors [1]. On pathology, Gliomas can be divided into low-grade gliomas (LGGs, including WHO I~II) and high-grade gliomas (HGGs, including WHO III~IV) according to their histological and molecular features [2]. Surgical resection combined with radiotherapy and chemotherapy are still the basic treatment for gliomas. LGGs grow slowly and has a favorable prognosis in general [3]; but HGGs are more aggressive with a 5-year relative survival rate of 15 - 58 % for anaplastic astrocytomas and of 6 -22 % for glioblastomas depending upon their age at diagnosis and various other prognostic factors [4]. Therefore, accurate assessment of the pathological grade of gliomas before surgery is of great clinical significance to determine the surgical resection range and to improve the survival rate of patients.

In the course of gliomas progression, the microstructures of tumors (tumor cell density, cell proliferation activity, and microvessel density, etc.) will undergo tremendous changes, reflecting the changes in histopathological characteristics of tumors [5]. Traditional morphological magnetic resonance imaging (MRI) can estimate the extent of histopathological differentiation of tumors based on cytotoxic edema, hemorrhage, necrosis, heterogeneity of signal intensity, degree and range of signal enhancement. However, studies have shown that the enhancement of gliomas is not completely consistent with tumor grade [6]. Roy et al. [7] reported that the sensitivity of conventional MRI to differentiate high-grade gliomas from low-grade gliomas ranged from 55.1% to 83.3%.

With the continuous development of MRI technology, multi-modal MRI technology has been used to evaluate the biological characteristics of gliomas from different perspectives and has potential application value in the grading of gliomas. Among them, artery spin labeling (ASL) and dynamic magnetic sensitivity enhanced perfusion imaging (DSC-MRI) are perfusion-weighted imaging techniques, while diffusion kurtosis imaging (DKI) is a diffusion magnetic resonance imaging technique. Quantitative perfusion parameters such as relative cerebral blood flow (rCBF) in ASL, relative cerebral blood volume (rCBV) in DSC-MRI and mean kurtosis (MK) in DKI are receiving more attention in the clinical application of preoperative grading of gliomas. Compared with low-grade gliomas, high-grade gliomas have a more abundant blood supply, so hemodynamic perfusion parameters will increase significantly [8]. The cellular pleomorphism and nuclear polymorphism in high-grade gliomas are more marked than those in low-grade gliomas, and the parameters associated with water molecular diffusion are also larger [9].

Most previous researches only utilized perfusion imaging or diffusion imaging to investigate the grading of gliomas, focusing on meta-analysis of diagnostic accuracy. The meta-analysis of quantitative parameters of the above imaging methods are lacking. Moreover, previous efforts only focused on the meta-analysis of diagnostic accuracy and lacked the meta-analysis on quantitative parameters. Due to the small sample size and incomplete parameters of individual studies, the reliability and repeatability of the technology are still unclear. Therefore, we propose a large sample-size comprehensive meta-analysis to resolve the conflicting findings in different studies and to evaluate the diagnostic performance of the quantitative perfusion and diffusion parameters in gliomas grading.

1.1 Literature Retrieval

A thorough search for literature from 2005 – 2019 relating to ASL, DSC-MRI or DKI in the grading of cerebral gliomas was performed, using sources from PubMed, Embase, Web of Science, CBM, China National Knowledge Infrastructure (CNKI), Wanfang Database. English search keywords were (astrocytoma or glioblastoma or glioma tumor or astrocytic tumor or gliomas or oligodendroglioma or oligodendroglial tumor) and (DKI or Diffusional Kurtosis or Kurtosis Imaging or kurtosis or DSC-MRI or Dynamic susceptibility contrast-enhanced MRI or Dynamic Susceptibility Contrast or DSC or rCBV or rCBF or ASL or arterial spin-labeling or perfusion or Continuous ASL perfusion or PASL or 3DpCASL or three-dimensional pseudo-continuous arterial spin labeling). In order to avoid missing documents, the combination of electronic search and manual search were performed.

1.2 Literature Inclusion and Exclusion Criteria

1.2.1Inclusion Criteria:

(1) ASL, DSC-MRI or DKI were used to differentiate gliomas of different grades; (2) At least one quantitative parameter of rCBF, rCBV and MK could be extracted or calculated from the study; (3) Only pathological diagnoses were included; (4) All subtypes of gliomas were included; (5) Fourfold table values of diagnostic tests can be obtained directly or indirectly, i.e. true-positive, true-negative, false-positive, and false-negative; (6)The quality evaluation scores of the included studies were at least 9 since high-quality studies are the basis for reliable meta-analysis.

1.2.2 Exclusion criteria:

(1) animal experiments, such as animal experiments of rats; (2) any unpublished conference abstracts, comments, duplication of literature or research; (3) similar studies written by the same author; (4) lack of key data; (5) use of other imaging methods (such as CT, PET, etc.).

1.3 Data Extraction from literature

The basic information includes first author’s name, country, the time of publication, patient age, tumor grade, number of cases, instrument type and field strength, journal of publication, methods, sequence and so on. Diagnostic information includes sensitivity, specificity, Fourfold table and the ROC curve with the corresponding area under the curve (AUC) value. If the information could not be obtained directly, the statistics were performed with the number of HGG and LGG cases and the sensitivity and specificity provided by the literature using RevMan 5.3 Software [10]. For articles providing sample size, median, extremum or quartile, methods of Luo et al. [11] and Wan et al. [12] were applied to estimate the mean and standard deviation of samples [13,14].

1.4 Quality Evaluation

Two researchers independently browsed the title and abstract of the retrieved literature, and read the full text of the literature that may meet the inclusion criteria, and finally determine whether to include them. If there were any disagreements especially on quality assessment, it was resolved by discussion with a third senior clinician. All selected studies were previously published, so there was no need for ethical review and approval or patients consent.

The quality assessment of diagnostic accuracy studies (QUADAS-2) recommended by Cochrane Collaboration was adopted as the evaluation criterion [15]. QUADAS-2 consists of the following key aspects: patient selection, index test, gold standard, flow and timing. Each of them was assessed in terms of risk of bias and signaling questions (yes/no/unclear) were included to assist in judgments. When the criterion is yes, the score increases by 1 point.

1.5 Data Analysis

1.5.1 Heterogeneity Test

Heterogeneity caused by different type of research design, age and gender of patients, pathological subtypes and other variables is a critical factor influencing the accuracy of results. The existence non-threshold effect was tested by Q-test and I^２ value using RevMan 5.3 Software. I^２＜50% indicates insignificant heterogeneity, and a fixed-effect model was applied to merge statistics. I^２≥50% indicates substantial heterogeneity, and a random-effect model was used to merge statistics. Q-test level was P< 0.05.

1.5.2 Meta-Analysis

RevMan 5.3 Software (Cochrane Collaboration, Oxford, UK) was used to calculate the effect size and 95% CI. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic ratio, AUC and its 95% CI were calculated by Stata 13.1, and SROC curves were constructed.

1.5.3 Publication bias

Publication bias was evaluated with Deek's funnel plot by Stata 13.1 software. P > 0.1 indicated that there was no publication bias.

1.5.4 Sensitivity Analysis

The stability of included studies was evaluated. We eliminated an individual study and calculated the pooled effect of the rest of studies.

2.1 Literature Retrieval Results

Fifty-four studies were selected for inclusion after reading the full text, of which 43 were in English and 11 were in Chinese. Patients include both adults and children. The studies were conducted in the following countries: China (n = 24), India (n = 2), Italy (n = 3), Spain (n = 1), Turkey (n = 1), Sweden (n = 2), Japan (n = 3), Norway (n = 1), the United States (n = 5), Canada (n = 1), Korea (n = 2), France (n = 1), Germany (n = 4). Denmark (n = 1), Belgium (n = 1), Brazil (n = 1), Australia (n = 1). Seven studies reported two methods. Of those studies including quantitative data and Continuous Variable Forest Map, 20 was in ASL, 22 in DSC-MRI, 15 in DKI. Of those studies including fourfold table data for meta-analysis of diagnostic tests, 19 was in ASL, 19 in DSC-MRI, 16 in DKI. The flowchart of retrieval process is presented in Figure 1. The basic information of the literature included is presented in Table 1.

Table1. Basic information of included studies

First author	Region	Average or median age	n	Gliomas grade(n)	Instrument Type and Field Strength	Technique	Diagnostic parameters	QUADAS-2 score
First author	Region	Average or median age	n	Gliomas grade(n)	Instrument Type and Field Strength	Technique	Diagnostic parameters	QUADAS-2 score
Arisawa 2018[16]	Japan	50(19–74)	34	I+II(15),III+IV(19)	GE 3.0T	ASL,DSC	rCBF, rCBV	12
Cebeci 2014[17]	Turkey	47±14	33	I+II(13),III+IV(20)	Philips 3.0T	ASL	rCBF	13
Fudaba 2014[18]	Japan	59.8±16.8	32	II(9),III(8),IV(15)	Siemens 3.0T	ASL	rCBF	13
Furtner 2014[19]	Australia	54±17	33	II(7),III(7),IV(19)	Siemens 3.0T	ASL	rCBF	12
Jiang J 2014[20]	China	42.7±15.3	23	I+II(10),III+IV(13)	GE 3.0T	ASL	rCBF	12
Kim 2008[21]	South Korea	43(19-74)	61	I+II(26),III+IV(35)	GE 1.5T	ASL	rCBF	11
Liao H 2016[22]	China	40.5	41	I+II(20),III+IV(21)	GE 3.0T	ASL	rCBF	11
Liu 2014[23]	China	8-75	38	I(5),II(17),III(7),IV(9)	GE 3.0T	ASL	rCBF	12
Ma 2017[24]	China	46±18	50	I+II(27),III+IV(23)	GE 3.0T	ASL,DSC	rCBF, rCBV	11
Qiao F 2015[25]	China	50(26–72)	28	I+II(11),III+IV(17)	GE 3.0T	ASL	rCBF	10
Roy 2013[7]	India	43	64	I(3),II(23),III(9),IV(29)	GE 3.0T	ASL	rCBF	11
Shen 2016[26]	China	42	52	I+II(25),III+IV(27)	GE 3.0T	ASL	rCBF	9
Tian Q 2015[27]	China	47(19–76)	45	I+II(19),III+IV(26)	GE 3.0T	ASL	rCBF	12
Wang N 2019[28]	China	48(23-81)	53	I(1),II(15),III(13),IV(24)	GE 3.0T	ASL	rCBF	10
Morana 2018[29]	Italy	9(2–17)	37	I(8),II(14),III(6),IV(9)	Philips 1.5T	ASL,DSC	rCBF, rCBV	10
Wolf 2005[30]	USA	50±12	26	I+II(7),III+IV(19)	Siemens 3.0T	ASL	rCBF	10
Xiao 2015[31]	China	43.3(6-74)	43	I+II(19),III+IV(24)	GE 3.0T	ASL	rCBF	11
Yang 2016[32]	China	51±15.34	43	II(15),III(15),IV(13)	Siemens 3.0T	ASL	rCBF	12
Zeng 2017[33]	China	50±13	58	II(13),III(17),IV(28)	GE 3.0T	ASL	rCBF	11
Zhao J 2016[34]	China	42(15–64)	18	I+II(8),III+IV(10)	GE 3.0T	ASL	rCBF	9
Van Cauter 2014[35]	Belgium	55	31/ 35	I+II(12),III+IV(19)-DSC I+II(13),III+IV(22)-DKI	Philips 3.0T	DSC ,DKI	rCBV, MK	9
Awasthi 2012[36]	India	16–65	76	I+II(21),III+IV(55)	GE 1.5T	DSC	rCBV	12
Boxerman 2016[37]	USA	52(19–80)	43	II(11),III(9),IV(23)	GE 1.5T	DSC	rCBV	12
Brendle 2018[38]	Germany	23-79	41	I+II(24),III+IV(17)	Siemens 3.0T	DSC	rCBV	14
Catalaa 2006[39]	USA	23-78	17	II(8),III(9)	GE 1.5T	DSC	rCBV	11
Cuccarini 2016[40]	Italy	39.6±12.6	68	I+II(42),III+IV(26)	Siemens 1.5T	DSC	rCBV	12
Dallery 2017[41]	France	9.4 (2.1–17.9)	30	I(7),II(4),III(7),IV(12)	GE 3.0T	DSC	rCBV	11
Falk 2014[42]	Sweden	22–79	25	II(18),III(7)	Philips 3.0T	DSC	rCBV	10
Fatima 2014[43]	Brazil	36.23± 16.95	38	I+II(16),III+IV(22)	GE 1.5T	DSC	rCBV	13
Hilario 2012[44]	Spain	23-79	162	II(32),III(29),IV(101)	GE 3.0T	DSC	rCBV	10
Huang 2015[45]	China	45(17-72)	35	I(2),II(12),III(9),IV(12)	Siemens 3.0T	DSC	rCBV	9
Kim 2013[46]	South Korea	35	63	II(9),III(16),IV(38)	Siemens 3.0T	DSC	rCBV	9
Law 2006[47]	USA	42(4–85)	73	II(31),III(16),IV(26)	Siemens 3.0T	DSC	rCBV	11
Wang M 2011[48]	China	42.9±14.7	23	I(1),II(5),III(8),IV(9)	Siemens 3.0T	ASL,DSC	rCBF, rCBV	9
Nguyen 2016[49]	Canada	54	43	I+II(10),III+IV(33)	Siemens 3.0T	DSC	rCBV	12
Santarosa 2016[8]	Italy	55.4 (22–79)	26	II(9),III(4),IV(13)	Philips 3.0T	DSC	rCBV	9
Server 2011[50]	Norway	57.73± 12.95	79	II(18),III(14),IV(47)	GE 3.0T	DSC	rCBV	10
Togao 2017[51]	Japan	14-75	34	I+II(20),III+IV(14)	Philips 3.0T	DSC	rCBV	12
Wang X 2016[52]	China	41±15	37	I+II(14),III+IV(23)	GE 3.0T	ASL,DKI	rCBF, MK	10
Falk Delgado 2017[53]	Sweden	48±15	35	II(23),III(12)	Philips 3.0T	DKI	MK	10
Gao A 2017[54]	China	48.66± 13.42	34	II(21),III(13)	Siemens 3.0T	DKI	MK	10
Hempel 2017[55]	USA	50±14	50	II(25),III(15),IV(10)	Siemens 3.0T	DKI	MK	11
Jiang 2015[56]	China	41±14	74	I(3),II(31),III(19),IV(21)	GE 3.0T	DKI	MK	10
Li 2016[57]	China	47	37	I+II(16),III+IV(21)	Siemens 3.0T	DKI	MK	9
Lin 2018[58]	China	42-75	96	I+II(84),III+IV(12)	GE 3.0T	DKI	MK	10
Maximov 2017[59]	Germany	18-59	24	II(8),III(8),IV(8)	GE 3.0T	DKI	MK	11
Qi 2018[60]	China	11-67	39	I+II(13),III+IV(26)	Siemens 3.0T	DKI	MK	9
Raab 2010[61]	Germany	56	18	II(5),III(13)	Siemens 3.0T	DKI	MK	11
Raja 2016[62]	Germany	35	18	II(9),III(9)	Philips 3.0T	DKI	MK	12
Tan 2016[63]	China	50	60	I+II(25),III+IV(35)	GE 3.0T	DKI	MK	11
Tietze 2015[64]	Denmark	42	34	II(12),III(7),IV(15)	Siemens 3.0T	DKI	MK	10
Zheng G 2014[65]	China	40.3±19.5	21	I(2),II(3),III(7),IV(9)	GE 3.0T	ASL,DSC	rCBF, rCBV	10
Wang Y 2017[66]	China	47.5 (25–75)	32	I+II(14),III+IV(18)	Siemens 3.0T	DKI	MK	10
Zhao 2019[67]	China	25-75	52	II(24),III(8),IV(20)	Siemens 3.0T	DKI	MK	12

2.2 Analysis

2.2.1 rCBF in ASL

Twenty studies assessing the difference of rCBF between HGGs and LGGs were included. Heterogeneity test showed that χ²= 66.79, I^２ = 72%, P < 0.001, indicating substantial heterogeneity. Therefore, the random effect model was applied to estimate the pooled rCBF. The pooled rCBF was 1.45 (1.12, 1.77), P < 0.001 (Figure 2).

2.2.2 rCBV in DSC-MRI

Twenty-two studies assessing the difference of rCBV between HGGs and LGGs were included. Heterogeneity test showed that χ²= 74.23, I^２= 72%, P < 0.001, indicating substantial heterogeneity. Therefore, the random effect model was applied to estimate the pooled rCBV. The pooled rCBV was 1.37 (1.08, 1.66), P < 0.001 (Figure 3).

2.2.3 MK in DKI

Fifteen studies assessing the difference of MK between HGGs and LGGs were included. Heterogeneity test showed that χ²= 46.39, I^２ = 70%, P < 0.001, indicating substantial heterogeneity. Therefore, the random effect model was applied to estimate the pooled MK. The pooled MK was 1.57 (1.21, 1.93), P < 0.001 (Figure 4).

2.2.4 Diagnostic Value

Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic ratio and area under curve were summarized according to the studies including fourfold table (Table 2). The results showed that rCBF had the highest diagnostic ratio (DOR) of 71 (31,163).The SROC curve suggested that rCBF had the highest AUC value of 0.95 (0.93,0.97), followed by MK 0.93 (0.91,0.95), and rCBV 0.91 (0.89,0.94) (Figure 5).

The incidence of gliomas is about 45% of all intracranial tumors [63]. The Fagan diagram of rCBF, rCBV and MK in the grading of gliomas is shown in Figure 6. Compared with 45% pre-test probability, the post-test probability of rCBF, rCBV and MK increases to 88%, 80% and 83%, respectively. The DOR value of rCBF is 71 (31,163), indicating a high pooled diagnostic accuracy.

Table2. The values of rCBF, rCBV and MK

index

Sen

(95％CI)

Spe

(95％CI)

PLR

(95%CI)

NLR

(95%CI)

DOR

(95%CI)

AUC

(95%CI)

rCBF

0.88

(0.83,0.92)

0.91

(0.84,0.94)

9.3

(5.4,16.0)

0.13

(0.09,0.20)

(31,163)

0.95

(0.93,0.97)

rCBV

0.92

(0.83,0.96)

0.81

(0.73,0.88)

5.0

(3.3,7.4)

0.10

(0.05,0.22)

(20,129)

0.91

(0.89,0.94)

0.88

(0.82,0.92)

0.86

(0.78,0.91)

6.2

(4.1,9.3)

0.14

(0.10,0.21)

(26,75)

0.93

(0.91,0.95)

2.2.5 Meta-regression

The results of meta-regression are shown in Table 3. Among the five covariates in ASL study, region, year of study, number of patients and QUADAS-2 score were all important factors contributing to heterogeneity except for field strength. Among the six covariates in DSC-MRI study, region, year of study, number of patients, field strength and QUADAS-2 score, none had significant impact on heterogeneity. Among the five covariates in DKI study, the year of study, age of patients, number of patients and QUADAS-2 score all had no significant impact on heterogeneity except for region.

Table3. meta-regression

	Variable	Subgroup	n	Overall estimate of meta-regression
	Variable	Subgroup	n	Sensitivity(95% CI)	p	Specificity(95% CI)	p
ASL	Region	China	14	0.89(0.84,0.94)	0.01	0.89(0.83,0.95)	0.71
	Region	others	5	0.86(0.77,0.95)	0.01	0.94(0.88,1.00)	0.71
	Year	2008-2014	8	0.87(0.80,0.93)	0.00	0.88(0.80,0.96)	0.01
	Year	2015-2019	11	0.89(0.83,0.95)	0.00	0.92(0.87,0.98)	0.01
	Number of patients	≤40	10	0.90(0.84,0.95)	0.00	0.93(0.87,0.99)	0.01
	Number of patients	＞40	9	0.87(0.81,0.93)	0.00	0.88(0.81,0.95)	0.01
	Field strength	1.5T	2	0.90(0.79,1.00)	0.21	0.96(0.90,1.00)	0.13
	Field strength	3.0T	17	0.88(0.83,0.93)	0.21	0.89(0.84,0.94)	0.13
	QUADAS-2 score	≤10	7	0.93(0.89,0.98)	0.00	0.94(0.89,1.00)	0.01
	QUADAS-2 score	＞10	12	0.84(0.79,0.90)	0.00	0.88(0.81,0.94)	0.01
DSC-MRI	Region	China	4	0.94(0.83,1.00)	0.77	0.88(0.74,1.00)	0.14
	Region	others	15	0.91(0.84,0.99)	0.77	0.80(0.72,0.88)	0.14
	Year	2006-2014	10	0.95(0.89,1.00)	0.07	0.80(0.69,0.90)	0.20
	Year	2015-2017	9	0.87(0.74,0.99)	0.07	0.83(0.73,0.93)	0.20
	Age	≤45	9	0.94(0.87,1.00)	0.31	0.85(0.75,0.95)	0.03
	Age	＞45	10	0.90(0.80,1.00)	0.31	0.79(0.68,0.89)	0.03
	Number of patients	≤40	10	0.95(0.88,1.00)	0.33	0.89(0.82,0.95)	0.56
	Number of patients	＞40	9	0.89(0.79,1.00)	0.33	0.72(0.62,0.83)	0.56
	Field strength	1.5T	4	0.98(0.93,1.00)	0.23	0.76(0.60,0.92)	0.00
	Field strength	3.0T	15	0.90(0.82,0.98)	0.23	0.83(0.75,0.91)	0.00
	QUADAS-2 score	≤10	10	0.94(0.88,1.00)	0.14	0.86(0.77,0.95)	0.01
	QUADAS-2 score	＞10	9	0.88(0.77,0.99)	0.14	0.77(0.66,0.88)	0.01
DKI	Region	China	9	0.89(0.83,0.95)	0.01	0.89(0.82,0.95)	0.01
	Region	others	7	0.86(0.77,0.94)	0.01	0.81(0.69,0.92)	0.01
	Year	2010-2015	4	0.85(0.75,0.95)	0.14	0.89(0.79,0.99)	0.06
	Year	2016-2019	12	0.89(0.84,0.94)	0.14	0.85(0.77,0.96)	0.06
	Age	≤48	9	0.85(0.78,0.92)	0.14	0.87(0.79,0.94)	0.02
	Age	＞48	7	0.91(0.85,0.97)	0.14	0.84(0.75,0.93)	0.02
	Number of patients	≤40	11	0.83(0.77,0.89)	0.32	0.88(0.81,0.94)	0.00
	Number of patients	＞40	5	0.93(0.89,0.98)	0.32	0.80(0.70,0.90)	0.00
	QUADAS-2 score	≤10	10	0.84(0.78,0.91)	0.18	0.87(0.80,0.94)	0.02
	QUADAS-2 score	＞10	6	0.92(0.87,0.97)	0.18	0.83(0.72,0.93)	0.02

2.2.6 Subgroup analysis

Subgroup analysis was successively carried out according to the region and technique in ASL, the region and magnetic resonance field strength in DSC-MRI, and the region in DKI. The results of subgroup analysis are shown in Table 4.

Table4. subgroup analysis

Sub

group

Cate

gory

Sen

(95％CI)

Spe

(95％CI)

PLR

(95% CI)

NLR

(95% CI)

DOR

(95% CI)

AUC

(95% CI)

ASL

Region

CHINA

0.30

0.88

(0.83,0.92)

0.89

(0.81,0.94)

8.4

(4.5,15.4)

0.13

(0.09,0.20)

(25,157)

0.94

(0.92,0.96)

other

0.35

0.89

(0.68,0.97)

0.94

(0.84,0.98)

14.0

(5.1,38.2)

0.11

(0.03,0.40)

123

(18,846)

0.96

(0.94,0.98)

Technique

PCASL

0.33

0.87

(0.82,0.91)

0.88

(0.81,0.93)

7.6

(4.4,13.1)

0.14

(0.10,0.21)

(24,116)

0.92

(0.90,0.94)

PASL

0.46

0.93

(0.75,0.98)

0.93

(0.80,0.98)

14.2

(4.2,48.1)

0.08

(0.02,0.31)

183

(19,1754)

0.98

(0.96,0.99)

DSC-MRI

Region

CHINA

0.23

0.91

(0.82,0.96)

0.90

(0.55,0.99)

9.6

(1.5,60.4)

0.10

(0.05,0.21)

(11,835)

0.89

(0.82,0.96)

other

0.00

0.92

(0.80,0.97)

0.80

(0.70,0.87)

4.6

(3.1,6.9)

0.10

(0.04,0.26)

(15,144)

0.90

(0.87,0.92)

Field strength

3.0 T

0.00

0.88

(0.79,0.94)

0.82

(0.73,0.89)

5.0

(3.2,7.7)

0.14

(0.08,0.26)

(17,73)

0.91

(0.88,0.93)

1.5 T

0.01

1.00

(0.12,1.00)

0.77

(0.57,0.90)

4.4

(2.1,9.1)

0.00

(0.00,10.67)

2976

(0,3125)

0.91

(0.89,0.93)

DKI

Region

CHINA

0.00

0.90

(0.81,0.95)

0.90

(0.79,0.95)

8.6

(4.3,17.2)

0.11

(0.06,0.21)

(35,160)

0.95

(0.93,0.97)

other

0.46

0.85

(0.76,0.91)

0.79

(0.69,0.87)

4.1

(2.7,6.2)

0.20

(0.12,0.32)

(10,44)

0.88

(0.85,0.91)

2.3 Publication bias

Deek's test was used to evaluate publication bias for studies containing fourfold tables. P> 0.1 indicated that there was no publication bias. 19 studies of ASL, 19 studies of DSC-MRI, 16 studies of DKI were eligible for Deek's test. Deeks funnel plot (Figure 7) showed no significant publication bias for all groups (P = 0.85, P = 0.45, P = 0.12, for ASL, DSC-MRI, DKI group, respectively).

2.4 Sensitivity Analysis

Sensitivity analysis is a key method for assessing heterogeneity and publication bias. We eliminated an individual study and calculated the pooled effect of the rest of studies. Compared with the pooled effect of all the included studies, we could determine the influence of individual study on the pooled effect. Results of this meta-analysis revealed that the included studies had no significant changes on the pooled value of rCBF and rCBV. However, the MK of Delgado et al. [53] showed significant influence on heterogeneity and publication bias before it was eliminated (I² = 70% to I² = 54% calculated by Revman5.3).

This meta-analysis revealed the pooled rCBF, rCBV and MK of HGGs were higher than those of LGGs, with the results statistically significant. The specificity of rCBF is the highest among all parameters, suggesting that the rate of misdiagnosis in rCBF is the lowest. The sensitivity of rCBV is the highest, suggesting that the rate of missed diagnosis in rCBV is the lowest. The results of meta-regression showed that there were many factors contributing to the heterogeneity of ASL studies, while the studies of DSC-MRI and DKI were relatively stable. Although three kinds of MRI techniques included in

this study could be applied to grade gliomas, the DOR suggested that rCBF in ASL had the highest diagnostics accuracy.

DSC-MRI perfusion imaging uses an exogenous contrast agent and relies on the acquisition of T2* images. DSC-MRI detects changes in MR signal as the contrast agent passes through the blood vessels, thus haemodynamic parameter (rCBV) can be indicative of microvascular properties such as vascular flow [8]. Compared to LGGs, HGGs have more abundant blood supply; therefore, the hemodynamic parameters (rCBV) would manifest notable increases significantly, which is consistent with the findings of Winkler et al. [68]. Awasthi et al. [36] observed that the microvessel density (MVD) and the positive expression of vascular endothelial growth factor (VEGF) had significant correlation with the pathological grade of gliomas and the rCBV value. Although the range of rCBV values reported in the literature amongst various types of gliomas, the most researchers observed higher rCBV in HGGs [69]. In this meta-analysis, we found that the discriminative values of sensitivity and specificity were 92% and 81% by rCBV between HGGs and LGGs.

ASL is a completely non-invasive MRI technique which measures blood flow by using magnetically labeled water protons in arterial blood as an endogenous tracer. It is not affected by the integrity of blood-brain barrier, therefore accurately evaluates gliomas microcirculation information, reflecting the situation of tumor angiogenesis, and thus the gliomas grade can be more accurately assessed [70, 71]. The relative rCBF has been widely used to discriminate between LGGs and HGGs. Although ASL suffers from low signal-to-noise ratio as well as sensitivity to motion, Cebeci and Luh et al. reported a strong correlation between ASL-derived CBF values and DSC-derived CBF values in brain tumours [17, 72]. Several studies had revealed that rCBF of ASL was a rigorous parameter of grading gliomas, thereby allowing it an alternative method of DSC-MRI [73-75].

Diffusion kurtosis imaging (DKI), first proposed by Professor Jensen of New York University in 2005, is a technique intending to explore the properties of non-gaussian diffusion of water molecules [76-77]. It has been proposed to more accurately characterise the complicated water diffusion in biological tissues. The most commonly used parameter of DKI is mean kurtosis (MK) which provides additional information about tumour heterogeneity. The cellular pleomorphism and nuclear polymorphism in HGGs are more significant than those in LGGs. The proliferation of interstitial vessels is also more abundant in HGGs and thus the MK value is higher [9]. Some studies indicated that MK was higher in HGGs. Raab et al. [61] found that the AUC of MK was 92.3% for differentiating HGGs from LGGs, which were in strong agreement with the findings in this meta-analysis.

Heterogeneity is common in meta-analysis. After excluding the research of Falk Delgado et al., the heterogeneity of MK decreased from 70% to 54%. Since there is moderate heterogeneity in this meta-analysis, clinical decisions should be made cautiously based on these results. Heterogeneity may be caused by the following aspects: (1) imbalance in the distribution of HGGs and LGGs: for instance, grade I gliomas were not studied in some research which resulted bias in case selection; (2) different experimental conditions set by researchers, such as different instrument models, parameter settings, post-processing methods, etc. (3) regional heterogeneity resulted from inclusion of literature from different countries and regions; (4) The region of interest (ROI) and the reference region were heterogeneously placed in the different studies, which may have an impact on the results.

The main limitations of this study are: 1. This study only focused on diagnostic value of ASL, DSC-MRI and DKI in distinguishing LGGs from HGGs, their role in the follow-up and each specific pathological grade of gliomas were not discussed; 2. Only research in Chinese and English were included, the sample size was relatively small; 3. Most studies used the WHO classification system without molecule genomics.

Quantitative parameters rCBF in ASL, rCBV in DSC-MRI and MK in DKI had excellent diagnostic performances for differentiating HGGs from LGGs. rCBF is a rigorous parameter of grading gliomas with AUC of 0.95, thereby allowing it an alternative method of DSC-MRI or DKI.

All selected studies were previously published, so there was no need for ethical review and approval or patients consent.

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: Not applicable.

Competing interests: The authors declare that they have no conflict of interest

Funding: Founded by Grant-in-aid for scientific research from the National Natural Science Foundation of China (No. 61976110), and the Natural Science Foundation of Shandong Province (ZR2013HL017)

Authors' contributions:

Chuanchen Zhang defined the topic and manuscript outline. Mingzhen Wu finished data collection. Jixin Luan, Xiaohui Wang and Lishan Qiao finished data analysis. Jixin Luan was a major contributor in writing the manuscript. Chuanchen Zhang and Guifang Guo finished manuscript quality control. All authors read and approved the final manuscript.

Acknowledgements: We would like to thank all the authors that tried to provide us with additional data upon our request.

ASL arterial spin labeling

DSC-MRI dynamic magnetic sensitivity contrast-enhanced magnetic resonance imaging

DKI diffusion kurtosis imaging

rCBF cerebral blood flow

rCBV relative cerebral blood volume

MK mean kurtosis

CBM China Biology Medicine disc

CNKI China National Knowledge Infrastructure

3DpCASL three-dimensional pseudo-continuous arterial spin labeling

CT computed tomography

PET positron emission tomography

[1].Wen PY, Kesari S. Malignant gliomas in adults. New England Journal of Medicine. 2008;359(5):492-507. doi: 10.1056/NEJMra0708126. PubMed PMID: WOS:000258039700007.

[2].Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803-20. doi: 10.1007/s00401-016-1545-1. PubMed PMID: WOS:000376277400001.

[3].Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncology. 2008;10(1):79-87. doi: 10.1215/15228517-2007-038. PubMed PMID: WOS:000252971200010.

[4].Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncol. 2019;21 Suppl 5:v1–v100. PubMed PMID: 31675094.

[5].Jia Z-z, Geng D-y, Liu Y, Chen X-r, Zhang J. Microvascular permeability of brain astrocytoma with contrast-enhanced magnetic resonance imaging: correlation analysis with histopathologic grade. Chinese Medical Journal. 2013;126(10):1953-6. doi: 10.3760/cma.j.issn.0366-6999.20111839. PubMed PMID: WOS:000319529200029.

[6].Bai Y, Lin Y, Tian J, Shi D, Cheng J, Haacke EM, et al. Grading of Gliomas by Using Monoexponential, Biexponential, and Stretched Exponential Diffusion-weighted MR Imaging and Diffusion Kurtosis MR Imaging. Radiology. 2016;278(2):496-504. doi: 10.1148/radiol.2015142173. PubMed PMID: WOS:000377702200024.

[7].Roy B, Awasthi R, Bindal A, Sahoo P, Kumar R, Behari S, et al. Comparative Evaluation of 3-Dimensional Pseudocontinuous Arterial Spin Labeling With Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging in Grading of Human Glioma. Journal of Computer Assisted Tomography. 2013;37(3):321-6. doi: 10.1097/RCT.0b013e318282d7e2. PubMed PMID: WOS:000319116700001.

[8].Santarosa C, Castellano A, Conte GM, Cadioli M, Iadanza A, Terreni MR, et al. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. European Journal of Radiology. 2016;85(6):1147-56. doi: 10.1016/j.ejrad.2016.03.020. PubMed PMID: WOS:000375944400016.

[9].Fieremans E, Jensen JH, Helpern JA. White matter characterization with diffusional kurtosis imaging. Neuroimage. 2011;58(1):177-88. doi: 10.1016/j.neuroimage.2011.06.006. PubMed PMID: WOS:000293548500020.

[10].LIU H, WU H, ZHANG N, LI Y. Methods of data extraction in meta-analysis of diagnostic accuracy study. Chin J Evid-Based Med. 2018;18(9):109-14.

[11].Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Statistical Methods in Medical Research. 2015;27(6).

[12].Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. Bmc Medical Research Methodology. 2014;14(1):135.

[13].LUO D, WAN X, LIU J, TONG T. How to estimate the sample mean and standard deviation from the sample size, median,extremes or quartiles? Chin J Evid-Based Med. 2017;17(11):1350-6.

[14].ZHANG B, KANG J, CHEN X. Methods to Combine Standard Deviations of Diff erent Subgroups in Meta-analysis. Chin J Evid-Based Med. 2016;16(7):851-4.

[15].Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine. 2011;155(8):529-U104. doi: 10.7326/0003-4819-155-8-201110180-00009. PubMed PMID: WOS:000296066300018.

[16].Arisawa A, Watanabe Y, Tanaka H, Takahashi H, Matsuo C, Fujiwara T, et al. Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors. Neuroradiology. 2018;60(6):599-608. doi: 10.1007/s00234-018-2024-2. PubMed PMID: WOS:000432292400004.

[17].Cebeci H, Aydin O, Ozturk-Isik E, Gumus C, Inecikli F, Bekar A, et al. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method. European Journal of Radiology. 2014;83(10):1914-9. doi: 10.1016/j.ejrad.2014.07.002. PubMed PMID: WOS:000341417000031.

[18].Fudaba H, Shimomura T, Abe T, Matsuta H, Momii Y, Sugita K, et al. Comparison of Multiple Parameters Obtained on 3T Pulsed Arterial Spin-Labeling, Diffusion Tensor Imaging, and MRS and the Ki-67 Labeling Index in Evaluating Glioma Grading. American Journal of Neuroradiology. 2014;35(11):2091-8. doi: 10.3174/ajnr.A4018. PubMed PMID: WOS:000345197700013.

[19].Furtner J, Schoepf V, Schewzow K, Kasprian G, Weber M, Woitek R, et al. Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms. American Journal of Neuroradiology. 2014;35(3):482-9. doi: 10.3174/ajnr.A3705. PubMed PMID: WOS:000333579400016.

[20].JIANG J, ZHAO L, YAO Y. Application of three-dimensional arterial spin labeling MR perfusion imaging in the pathology grading of astrocytoma before surgery. Radiol Prac. 2014;29(8):896-900.

[21].Kim MJ, Kim HS, Kim JH, Cho KG, Kim SY. Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading. Acta Radiol. 2008;49(4):450-7. Epub 2008/04/17. doi: 10.1080/02841850701881820. PubMed PMID: 18415790.

[22].LIAO H, XIAO X, DAI Z, LIU Z, YU J. A study of 3D-PCASL in brain gliomas at 3.0T MR. J Prac Radiol. 2016;32(3):441-5.

[23].Liu ZH, Liao HB, Yin JH, Li YF. Using R2(star) values to evaluate brain tumours on magnetic resonance imaging: Preliminary results. European Radiology. 2014;24(3):693-702. doi: 10.1007/s00330-013-3057-x. PubMed PMID: WOS:000332658100018.

[24].Ma H, Wang Z, Xu K, Shao Z, Yang C, Xu P, et al. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery. Experimental and Therapeutic Medicine. 2017;13(6):2691-8. doi: 10.3892/etm.2017.4370. PubMed PMID: WOS:000401080000015.

[25].QIAO F, LI Y, WANG C. Application of 3D whole -brain arterial spin-labeling imaging and dynamic contrast-enhanced MR imaging for the preoperative evaluation in brain gliomas. J Prac Radiol. 2015;31(3):360-4.

[26].Shen N, Zhao L, Jiang J, Jiang R, Su C, Zhang S, et al. Intravoxel incoherent motion diffusion-weighted imaging analysis of diffusion and microperfusion in grading gliomas and comparison with arterial spin labeling for evaluation of tumor perfusion. J Magn Reson Imaging. 2016;44(3):620-32. Epub 2016/02/18. doi: 10.1002/jmri.25191. PubMed PMID: 26880230.

[27].TIAN Q, ZHANG X, XU F. The application of MR 3D-ASL in preoperative prediction of tumor grade in glioma patients. J Prac Radiol. 2015;31(11):1758-61.

[28].Wang N, Xie SY, Liu HM, Chen GQ, Zhang WD. Arterial spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status. Translational Oncology. 2019;12(5):749-56. doi: 10.1016/j.tranon.2019.02.013. PubMed PMID: WOS:000463598100008.

[29].Morana G, Tortora D, Stagliano S, Nozza P, Mascelli S, Severino M, et al. Pediatric astrocytic tumor grading: comparison between arterial spin labeling and dynamic susceptibility contrast MRI perfusion. Neuroradiology. 2018;60(4):437-46. doi: 10.1007/s00234-018-1992-6. PubMed PMID: WOS:000427696600013.

[30].Wolf RL, Wang JJ, Wang SM, Melhem ER, O'Rourke DM, Judy KD, et al. Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 tesla. Journal of Magnetic Resonance Imaging. 2005;22(4):475-82. doi: 10.1002/jmri.20415. PubMed PMID: WOS:000232317700005.

[31].Xiao H-F, Chen Z-Y, Lou X, Wang Y-L, Gui Q-P, Wang Y, et al. Astrocytic tumour grading: a comparative study of three-dimensional pseudocontinuous arterial spin labelling, dynamic susceptibility contrast-enhanced perfusion-weighted imaging, and diffusion-weighted imaging. European Radiology. 2015;25(12):3423-30. doi: 10.1007/s00330-015-3768-2. PubMed PMID: WOS:000364517000002.

[32].Yang S, Zhao B, Wang G, Xiang J, Xu S, Liu Y, et al. Improving the Grading Accuracy of Astrocytic Neoplasms Noninvasively by Combining Timing Information with Cerebral Blood Flow: A Multi-TI Arterial Spin-Labeling MR Imaging Study. American Journal of Neuroradiology. 2016;37(12):2209-16. doi: 10.3174/ajnr.A4907. PubMed PMID: WOS:000390082800007.

[33].Zeng Q, Jiang B, Shi F, Ling C, Dong F, Zhang J. 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the Preoperative Evaluation of Gliomas. American Journal of Neuroradiology. 2017;38(10):1876-83. doi: 10.3174/ajnr.A5299. PubMed PMID: WOS:000411955100015.

[34].ZHAO J, LIANG L, TAN Z. The Value of 3D-ASL in the Preoperative Grading of Gliomas Journal of Rare and Uncommon Diseases. 2016;123(6):7-9.

[35]. Van Cauter S, De Keyzer F, Sima DM, Sava AC, D'Arco F, Veraart J, et al. Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas. Neuro-Oncology. 2014;16(7):1010-21. doi: 10.1093/neuonc/not304. PubMed PMID: WOS:000338126100014.

[36].Awasthi R, Rathore RKS, Soni P, Sahoo P, Awasthi A, Husain N, et al. Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology. 2012;54(3):205-13. doi: 10.1007/s00234-011-0874-y. PubMed PMID: WOS:000300665600003.

[37].Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. American Journal of Neuroradiology. 2006;27(4):859-67. PubMed PMID: WOS:000236822500031.

[38].Brendle C, Hempel J-M, Schittenhelm J, Skardelly M, Reischl G, Bender B, et al. Glioma grading by dynamic susceptibility contrast perfusion and C-11-methionine positron emission tomography using different regions of interest. Neuroradiology. 2018;60(4):381-9. doi: 10.1007/s00234-018-1993-5. PubMed PMID: WOS:000427696600007.

[39].Catalaa I, Henry R, Dillon WP, Graves EE, McKnight TR, Lu Y, et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. Nmr in Biomedicine. 2006;19(4):463-75. doi: 10.1002/nbm.1059. PubMed PMID: WOS:000238883100004.

[40].Cuccarini V, Erbetta A, Farinotti M, Cuppini L, Ghielmetti F, Pollo B, et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro-Oncology. 2016;126(2):279-88. doi: 10.1007/s11060-015-1960-5. PubMed PMID: WOS:000368728300008.

[41].Dallery F, Bouzerar R, Michel D, Attencourt C, Promelle V, Peltier J, et al. Perfusion magnetic resonance imaging in pediatric brain tumors. Neuroradiology. 2017;59(11):1143-53. doi: 10.1007/s00234-017-1917-9. PubMed PMID: WOS:000412758900013.

[42].Falk A, Fahlstrom M, Rostrup E, Berntsson S, Zetterling M, Morell A, et al. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology. 2014;56(12):1031-8. doi: 10.1007/s00234-014-1426-z. PubMed PMID: WOS:000345297100002.

[43].de Fatima Vasco Aragao M, Law M, Batista de Almeida D, Fatterpekar G, Delman B, Bader AS, et al. Comparison of Perfusion, Diffusion, and MR Spectroscopy between Low-Grade Enhancing Pilocytic Astrocytomas and High-Grade Astrocytomas. American Journal of Neuroradiology. 2014;35(8):1495-502. doi: 10.3174/ajnr.A3905. PubMed PMID: WOS:000340517400010.

[44].Hilario A, Ramos A, Perez-Nunez A, Salvador E, Milian JM, Lagares A, et al. The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas. American Journal of Neuroradiology. 2012;33(4):701-7. doi: 10.3174/ajnr.A2846. PubMed PMID: WOS:000302842900021.

[45].HUANG J, LI X, KANG H, ZHANG Y, ZHANG W. Dynamic contrast enhanced magnetic resonance imaging and dynamic susceptibility contrast magnetic resonance imaging in grading of glioma. J Third Mil Med Univ. 2015;37(7):672-7.

[46].Kim H, Choi SH, Kim J-H, Ryoo I, Kim SC, Yeom JA, et al. Gliomas: Application of Cumulative Histogram Analysis of Normalized Cerebral Blood Volume on 3 T MRI to Tumor Grading. Plos One. 2013;8(5). doi: 10.1371/journal.pone.0063462. PubMed PMID: WOS:000319330200042.

[47].Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, et al. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. American Journal of Neuroradiology. 2006;27(9):1975-82. PubMed PMID: WOS:000241316400038.

[48].WANG M, WANG D, HONG X, WANG J. Comparison of arterial spin labelingand dynamic susceptibilitycontrast -enhanced MR imaging for the preoperation evaluation of tumor grade in brain gliomas. J Med Imaging. 2011;21(7):954-8.

[49].Nguyen TB, Cron GO, Bezzina K, Perdrizet K, Torres CH, Chakraborty S, et al. Correlation of Tumor Immunohistochemistry with Dynamic Contrast-Enhanced and DSC-MRI Parameters in Patients with Gliomas. American Journal of Neuroradiology. 2016;37(12):2217-23. doi: 10.3174/ajnr.A4908. PubMed PMID: WOS:000390082800008.

[50].Server A, Graff BA, Orheim TED, Schellhorn T, Josefsen R, Gadmar OB, et al. Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading. Neuroradiology. 2011;53(6):435-47. doi: 10.1007/s00234-010-0770-x. PubMed PMID: WOS:000290772400006.

[51].Togao O, Hiwatashi A, Yamashita K, Kikuchi K, Keupp J, Yoshimoto K, et al. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging. European Radiology. 2017;27(2):578-88. doi: 10.1007/s00330-016-4328-0. PubMed PMID: WOS:000392142000017.

[52].WANG X. (2016) Diffusion kurtosis imaging combined with Arterial spin labeling in the evaluation of grading of brain glioma. Dissertation, Zunyi Medical University.

[53].Delgado AF, Fahlstrom M, Nilsson M, Berntsson SG, Zetterling M, Libard S, et al. Diffusion kurtosis imaging of gliomas grades II and III - a study of perilesional tumor infiltration, tumor grades and subtypes at clinical presentation. Radiology and Oncology. 2017;51(2):121-9. doi: 10.1515/raon-2017-0010. PubMed PMID: WOS:000401697000001.

[54].GAO A. (2017) The application of MR Diffusion kurtosis imaging in Glioma Grading . Dissertation, Zhengzhou University.

[55].Hempel J-M, Bisdas S, Schittenhelm J, Brendle C, Bender B, Wassmann H, et al. In vivo molecular profiling of human glioma using diffusion kurtosis imaging. Journal of Neuro-Oncology. 2017;131(1):93-101. doi: 10.1007/s11060-016-2272-0. PubMed PMID: WOS:000393065400011.

[56].Jiang R, Jiang J, Zhao L, Zhang J, Zhang S, Yao Y, et al. Diffusion kurtosis imaging can efficiently assess the glioma grade and cellular proliferation. Oncotarget. 2015;6(39):42380-93. doi: 10.18632/oncotarget.5675. PubMed PMID: WOS:000366119600074.

[57].Li F, Shi W, Wang D, Xu Y, Li H, He J, et al. Evaluation of histopathological changes in the microstructure at the center and periphery of glioma tumors using diffusional kurtosis imaging. Clinical Neurology and Neurosurgery. 2016;151:120-7. doi: 10.1016/j.clineuro.2016.10.018. PubMed PMID: WOS:000389292400022.

[58].Lin L, Bhawana R, Xue Y, Duan Q, Jiang R, Chen H, et al. Comparative Analysis of Diffusional Kurtosis Imaging, Diffusion Tensor Imaging, and Diffusion-Weighted Imaging in Grading and Assessing Cellular Proliferation of Meningiomas. American Journal of Neuroradiology. 2018;39(6):1032-8. doi: 10.3174/ajnr.A5662. PubMed PMID: WOS:000437261600012.

[59].Maximov II, Tonoyan AS, Pronin IN. Differentiation of glioma malignancy grade using diffusion MRI. Physica Medica-European Journal of Medical Physics. 2017;40:24-32. doi: 10.1016/j.ejmp.2017.07.002. PubMed PMID: WOS:000410701400004.

[60].Qi X-X, Shi D-F, Ren S-X, Zhang S-Y, Li L, Li Q-C, et al. Histogram analysis of diffusion kurtosis imaging derived maps may distinguish between low and high grade gliomas before surgery. European Radiology. 2018;28(4):1748-55. doi: 10.1007/s00330-017-5108-1. PubMed PMID: WOS:000426645600045.

[61].Raab P, Hattingen E, Franz K, Zanella FE, Lanfermann H. Cerebral Gliomas: Diffusional Kurtosis Imaging Analysis of Microstructural Differences. Radiology. 2010;254(3):876-81. doi: 10.1148/radiol.09090819. PubMed PMID: WOS:000274796200030.

[62].Raja R, Sinha N, Saini J, Mahadevan A, Rao KVLN, Swaminathan A. Assessment of tissue heterogeneity using diffusion tensor and diffusion kurtosis imaging for grading gliomas. Neuroradiology. 2016;58(12):1217-31. doi: 10.1007/s00234-016-1758-y. PubMed PMID: WOS:000390406600008.

[63].Tan Y, Zhang H, Zhao R-F, Wang X-C, Qin J-B, Wu X-F. Comparison of the values of MRI diffusion kurtosis imaging and diffusion tensor imaging in cerebral astrocytoma grading and their association with aquaporin-4. Neurology India. 2016;64(2):265-72. doi: 10.4103/0028-3886.177621. PubMed PMID: WOS:000372172500014.

[64].Tietze A, Hansen MB, Ostergaard L, Jespersen SN, Sangill R, Lund TE, et al. Mean Diffusional Kurtosis in Patients with Glioma: Initial Results with a Fast Imaging Method in a Clinical Setting. American Journal of Neuroradiology. 2015;36(8):1472-8. doi: 10.3174/ajnr.A4311. PubMed PMID: WOS:000359657400016.

[65].ZHENG G. Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging in the pre-operation evaluation of brain gliomas. Modern Instruments & Medical Treatment. 2014;20(6).

[66].Wang Y, Zhao J, Xinbei LI, Yan X, Jiang L, Yang Z, et al. Efficacy of diffusion kurtosis imaging in grading gliomas and predicting cell proliferation. Chinese Journal of Medical Imaging Technology. 2017;33(2):177-82.

[67].Zhao J, Wang Y-l, Li X-b, Hu M-s, Li Z-h, Song Y-k, et al. Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status. Journal of Neuro-Oncology. 2019;141(1):195-203. doi: 10.1007/s11060-018-03025-7. PubMed PMID: WOS:000456968600019.

[68].Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, Mitteregger G, et al. Imaging Glioma Cell Invasion In Vivo Reveals Mechanisms of Dissemination and Peritumoral Angiogenesis. Glia. 2009;57(12):1306-15. doi: 10.1002/glia.20850. PubMed PMID: WOS:000268307000005.

[69].Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I. Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. American Journal of Neuroradiology. 2005;26(9):2187-99. PubMed PMID: WOS:000232547800006.

[70].Di N, Pang H, Dang X, Cheng W, Yan R, Wu J, et al. Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies. Neuroradiology. 2017;59(1):1-9.

[71].Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology. 2003;228(2):523-32. doi: 10.1148/radiol.2282020409. PubMed PMID: WOS:000184381100034.

[72].Luh WM, Wong EC, Bandettini PA, Hyde JS. QUIPSS II with thin-slice TI1 periodic saturation: A method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magnetic Resonance in Medicine. 1999;41(6):1246-54. doi: 10.1002/(sici)1522-2594(199906)41:6<1246::Aid-mrm22>3.0.Co;2-n. PubMed PMID: WOS:000081422500022.

[73].Jarnum H, Steffensen EG, Knutsson L, Frund E-T, Simonsen CW, Lundbye-Christensen S, et al. Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging. Neuroradiology. 2010;52(4):307-17. doi: 10.1007/s00234-009-0616-6. PubMed PMID: WOS:000275422000006.

[74].White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, et al. Regional and Voxel-Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) and Arterial Spin Labeling (ASL) in Brain Tumors. Journal of Neuroimaging. 2014;24(1):23-30. doi: 10.1111/j.1552-6569.2012.00703.x. PubMed PMID: WOS:000329509100005.

[75].Tourdias T, Rodrigo S, Oppenheim C, Naggara O, Varlet P, Amoussa S, et al. Pulsed arterial spin labeling applications in brain tumors: Practical review. Journal of Neuroradiology. 2008;35(2):79-89. doi: 10.1016/j.neurad.2007.11.007. PubMed PMID: WOS:000256815300003.

[76].Jensen JH, Helpern JA, Ramani A, Lu HZ, Kaczynski K. Diffusional kurtosis imaging: The quantification of non-Gaussian water diffusion by means of magnetic resonance imaging. Magnetic Resonance in Medicine. 2005;53(6):1432-40. doi: 10.1002/mrm.20508. PubMed PMID: WOS:000229468200025.

[77].Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. Nmr in Biomedicine. 2010;23(7):698-710. doi: 10.1002/nbm.1518. PubMed PMID: WOS:000283014300004.

PDF

Journal Publication

published 24 Aug, 2020

Read the published version in Radiation Oncology →

Editorial decision: Accept
11 Aug, 2020
Editor assigned by journal
10 Aug, 2020
Submission checks completed at journal
09 Aug, 2020
Editor invited by journal
09 Aug, 2020

You are reading this latest preprint version

The diagnostic value of quantitative analysis of ASL, DSC-MRI and DKI in the Grading of Cerebral Gliomas: A Meta-Analysis

Status:

Journal Publication

Version 3

Abstract

Figures

Background

Materials And Methods

Results

Discussion

Conclusion

Declarations

Abbreviations

References

Status:

Journal Publication

Version 3